Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns

Extensive burns are a severe form of trauma that, according to the World Health Organization, cause more than 180,000 deaths worldwide each year. Despite advances in modern medicine, sepsis and other infectious complications remain the leading causes of high mortality among severely burned patients. The Efferon® LPS NEO device, originally developed for sepsis, targets both primary and secondary inflammatory mediators. This technology also shows promise in burn injury, which is characterized by a complex inflammatory response. Burn trauma triggers the release of cytokines and damage-associated molecular patterns (DAMPs), while increased intestinal permeability and endotoxin translocation may introduce pathogen-associated molecular patterns (PAMPs). Addressing both DAMPs and PAMPs is therefore critical for effective burn injury management. The goal of the study is to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS NEO device in pediatric burn injury

Inclusion criteria

• Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29)
• Frank index >90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion)
• Start of hemoadsorption no later than 5 days after admission to the ICU
• The patient should receive adequate infusion therapy (at least 30 mL/kg) from the moment of inclusion in the study until the first sorption
• The patient's condition allows Efferon LPS NEO therapy to be performed for at least 6 hours

Exclusion criteria

• Presence of end-stage renal disease
• Acute pulmonary embolism, confirmed by CT scan
• Uncontrolled bleeding (acute blood loss within the last 24 hours)